DeviceTalks Podcast Network

DeviceTalks Podcast Network

By DeviceTalks Podcast NetworkNewsHealth & FitnessTechnologyTech News
Download on the App Store

All DeviceTalks Podcast Network episodes

  • Boston Scientific's Paudie O'Connor on managing supply chain volatility and sustainability
    In this episode of Boston Scientific Talks, Paudie O'Connor, SVP of Global Supply Chain, reflects on how Boston Scientific is overcoming initial supply chain challenges by establishing a new operational efficiency and sustainability standard.
    Additionally, O'Connor highlights Boston Scientific's strategic shift towards more sustainable practices, including a significant reduction in carbon footprint by transitioning from air to ocean freight, reducing carbon footprint by 96%, and aiming for a 90% ocean freight rate by 2026. This shift necessitates infrastructural investments, such as building sterilization facilities closer to manufacturing sites, enabling direct market shipping, and transitioning from air to sea where feasible.
    The discussion also covers innovations in packaging, with a move towards digital instructions and tailored packaging for different markets. This approach aligns with environmental goals while catering to diverse regulatory requirements. Lastly, O'Connor speaks to the role of supplier partnerships in achieving these ambitious targets, underlining Boston Scientific's commitment to not only navigating but also redefining the supply chain norms in the medical device industry.
    Listen to this episode of the DeviceTalks Weekly Podcast to hear more about Paudie O'Connor's career and work at Boston Scientific. https://www.devicetalks.com/what-boston-scientifics-evolving-supply-chain-strategy-means-for-partners-productivity-and-ma/ 
    Thank you to Xometry for sponsoring this episode. Visit www.xometry.com to learn more about Xometry and get an instant quote or injection molding quote today. 
    Thank you for listening to the Boston Scientific Podcast.
    Subscribe to this podcast on every major podcast platform.
    26 min
  • Stryker’s neurovascular president Jim Marucci on Cerus acquisition, Target Tetra and AI/AR potential
    In this episode of StrykerTalks, neurovascular president Jim Marucci discusses the company's latest advancements in neurovascular technology and how that, and its expanding global footprint, are shaping the future of its neurovascular division.
    Marucci details the company's recent strategic acquisition of Cerus Endovascular, which has increased Stryker's capabilities in treating wide-neck bifurcated aneurysms. Furthering Stryker's goal to simplify procedures, reduce costs, and improve patient outcomes.
    The conversation also touches on developing new products like the Target Tetra detachable coil for smaller aneurysms and the potential of emerging technologies like AI, AR, and VR in neurovascular procedures. Marucci anticipates these technologies will play a crucial role in advancing the field and improving access to care globally.
    Tune in for a comprehensive overview of Stryker's current strategies, product innovations, and future directions in the neurovascular sector, underlining its commitment to enhancing stroke care and neurovascular treatments worldwide.
    Thank you to Zeus for sponsoring this episode. To learn more about how Zeus works with medical device companies, visit www.zeusinc.com.
    Thank you for listening to the StrykerTalks Podcast.
    Subscribe to this podcast on every major podcast platform.
    31 min
  • How do I Drive Medtech Product Development? With Kirsten Carroll, Kandu Health
    In the first episode of the newest series from the DeviceTalks Podcast Network, our guest Kirsten Carroll, CEO of Kandu Health shares her insights on the medical device product development cycle from the perspective of "The Product Director."
    With more than a decade and a half in product management for Boston Scientific and Stryker Neurovascular, Kirsten discusses the roles of product management, design verification, and design validation in ensuring a successful product launch. She also highlights the significance of generating clinical evidence and tailoring it to different stakeholders. Kirsten's key message is the value of effective communication and collaboration in developing and launching medical devices.
    TL;DR Key take-aways:
    1. Collaboration between different teams is crucial in the medical device product development cycle.
    2. User needs should be clearly defined and translated into specifications for design verification.
    3. Design validation involves testing the product with the intended users to ensure it meets their expectations.
    4. Clinical evidence generation should align with the specific needs of different stakeholders.
    5. Effective communication and collaboration are essential for successful product development and launch.
    Thank you to our sponsors Aptyx, Catalyze Healthcare, Confluent, and Cretex Medical for providing vital support.
    aptyx.com
    catalyzehealthcare.com
    confluentmedical.com
    cretex.com
    Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode.
    Thank you for supporting MedtechWOMEN Talks.
    32 min
  • Does Medtech Need a New Way? Hear from Imperative Care’s Fred Khosravi, McKinsey’s Delphine Zurkiya
    In this episode, we’ll hear from Fred Khosravi, CEO of Imperative Care, a medical device company that is taking an unusually holistic approach to helping people who have suffered strokes. Host Tom Salemi interviewed the successful medical device CEO at DeviceTalks West.
    Before that we’ll talk with Delphine Zurkiya, senior partner at McKinsey & Co., about a new report that lays out a blueprint for medical device companies to improve efficiencies in R&D and customer outreach.
    But first we’ll highlight our newest member of the DeviceTalks Podcast family – AI Meets Life Sci – with co-hosts Kayleen Brown and Brian Buntz!
    Thank you for listening to the DeviceTalks Weekly Podcast.
    Subscribe to the DeviceTalks Podcast Network on any major podcast application.
    1 hr 14 min
  • The episode where Mayo Clinic & Anumana transform ECG with AI; ConcertAI dishes on next-gen trials
    Welcome to DeviceTalks AI, a DeviceTalks podcast offering a comprehensive look into the intersection of AI and the medical device industry from two unique perspectives.
    In the first segment, Paul Friedman, MD, Chair of the Department of Cardiovascular Medicine at Mayo Clinic, and Dave McMullin, Chief Business Officer of Anumana, discuss the groundbreaking collaboration between Mayo Clinic and Anumana in applying AI to enhance cardiovascular diagnostics, particularly through ECGs. They explore how AI can detect cardiac conditions early, with a focus on the EAGLE study's findings on AI-enhanced ECGs, and discuss Anumana's role in transforming these AI innovations into accessible medical devices.
    In the second segment, Jeff Elton, PhD, CEO of ConcertAI, speaks to the transformative role of AI in clinical trials. He sheds light on AI's capabilities in improving patient selection for clinical trials and streamlining processes within life sciences. Dr. Elton emphasizes the broader implications of AI, from enhancing patient care to accelerating the development of new treatments, and discusses the ethical considerations of AI integration in healthcare.These interviews provide insights into the evolving roles of AI in various sectors like medtech, pharma, and biotech, showcasing its potential in transforming healthcare and research methodologies.
    But that's not all! Join us for the next episode of DeviceTalks AI, which features an interview with the Global Business Leader for Health and Life Sciences at Microsoft.
    Catch the full episode on all major podcast platforms and the DeviceTalks YouTube to dive deeper into the exciting convergence of AI and medtech.
    Thank you to our contributors, some of who include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing vital support. To learn more about our contributors, visit: www.catalyzehealthcare.com and www.smarttrak.com.
    Thank you for listening to DeviceTalks AI.
    1 hr 8 min
  • Hear Why J&J Medtech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of GLP-1 drugs
    In this week’s episode we’ll speak with Rocco De Bernardis, Global President of OTTAVA, Johnson & Johnson MedTech. This week, J&J MedTech announced it was filing an IDE to begin clinical trials on its surgical robotics system, Ottava, in 2024. But what does this mean? What does Ottava look like? Why does J&J MedTech think it has what it takes to win over surgeons? And what does the future look like for the company’s surgical robotics platform?
    Co-hosts Tom Salemi and Chris Newmarker also chat with Karthik Bolisetty, senior associate at VC firm Gilde Healthcare, about the impact GLP-1 drugs could have on medical device start-ups. How does Gilde see the weight loss drugs impacting its portfolio and future investments?
    Finally, Gregg Tobin, CEO of Aptyx, our episode sponsor, talks about how the company’s new name better reflects its capabilities. Go to Aptyx.com for more information.
    Thanks for listening to the DeviceTalks Weekly podcast.
    Subscribe to the DeviceTalks Podcast Network on any major podcast application.
    1 hr 3 min
  • Boston Scientific's EP leaders Stein and Spadea-Anello discuss the next leap in cardiac ablation
    In this episode of Boston Scientific Talks, Boston Scientific's electrophysiology leaders, Ken Stein, MD, SVP, Global Chief Medical Officer and Nick Spadea-Anello, Global President of Electrophysiology, offer a deep dive into the transformative potential of the FARAPULSE Pulsed Field Ablation System. They discuss the strategic development and clinical advantages of this innovative technology, emphasizing its ability to target cardiac tissue while minimizing the risk of collateral damage to vital structures like the esophagus.
    The duo also explores the synergistic potential of combining PFA with devices like the WATCHMAN for stroke prevention, painting a picture of a more streamlined, patient-centric approach to cardiac care. With a keen eye on the future, they discuss the vision for expanding PFA's applications, including its role in treating a broader spectrum of arrhythmias and its adaptability to various procedural settings. Tune in to learn more about Boston Scientific's forward-thinking approach to cardiac ablation.
    Thank you to Dassault Systèmes for sponsoring this episode. To learn how Dassault Systèmes enables innovation in medtech, visit www.medtecheco.com/lifecycle.
    Thank you for listening to the Boston Scientific Podcast.
    Subscribe to this podcast on every major podcast platform.
    44 min
  • Intuitive's Dave Rosa shares insights on surgical robotics’ evolution, offers advice to new players
    In this special episode of IntuitiveTalks, recorded live from DeviceTalks West, Dave Rosa, President of Intuitive, shares the experience of the company's pioneering role in surgical robotics. Rosa reflects on the initial skepticism faced by the company and the subsequent validation of their work as the industry has grown to embrace robotic assistance in surgery. He also discusses the balance between innovation and the practicalities of scaling a business, emphasizing the importance of reliability and supply chain management in healthcare technology.
    Rosa also addresses the future of surgical robotics, hinting at a shift towards more compact and specialized devices that could transform patient care. He highlights the economic benefits of robotic surgery, particularly its potential to reduce the overall costs of healthcare while improving surgical outcomes.
    A must for all medtech stakeholders, this episode offers a thoughtful perspective on leading a company at the forefront of medical technology. Rosa's conversation is a blend of personal experience and professional insights, providing valuable lessons on growth, adaptation, and the continuous effort to improve surgical care.
    Thanks to maxon Group for sponsoring this episode. Visit https://www.maxongroup.us/maxon/view/content/medical to learn more about how maxon Group works with medical device companies.
    Thank you for listening to the IntuitiveTalks Podcast.
    Subscribe to this podcast on every major podcast platform.
    39 min
  • Abbott’s Tyler outlines vascular’s move to predictive modeling, diversifying trials & next-gen tech
    In this special episode of AbbottTalks, recorded live from DeviceTalks West, Julie Tyler, president of Abbott's Vascular business, discusses the company's strategic evolution and commitment to comprehensive patient care, including a new technology, the Esprit BTK, intended to be released next year.
    Additionally, Tyler provides an insider's perspective on Abbott's integration of Cardiovascular Systems Inc., revealing how this move enhances Abbott's portfolio and positions the company at the forefront of vascular health. Tyler's vision extends beyond current interventions, aiming to leverage data and predictive modeling to improve patient outcomes and potentially reduce the need for later-stage interventions.
    With a patient-centric approach, Tyler also discusses the challenges and successes in diversifying clinical trial demographics and expanding global reach. This episode is a must-listen for those interested in how strategic acquisitions and a holistic health model can redefine patient care.
    Thank you to Resonetics for sponsoring this episode. To learn more about how Resonetics works with medical device companies, visit https://resonetics.com/.
    Thank you for listening to the AbbottTalks Podcast. Subscribe to this podcast on every major podcast platform.
    1 hr
  • Qiagen CEO on learning to love diagnostics and why he’s worried we forgot lessons from the pandemic
    In this week’s episode, Qiagen CEO Thierry Bernard gives us a look inside the diagnostics leader both today and a few years ago when it was responded to the world’s dire need for diagnostics.
    Bernard takes us back to the early days of the pandemic, including his perspective on how different countries responded to the crisis. We’ll also hear his vision for the future of diagnostics including how Qiagen will make testing even simpler.
    At the start of the show, Host Tom Salemi and Chris Newmarker, executive editor of life sciences, talk with Senior Editor Danielle Kirsh about the recently released Women in Medtech issue of Medical Design and Outsourcing magazine. Kirsh shares data she’s collected on how many women hold senior positions in the medical device industry. We’re seeing some progress, but not enough.
    Thanks for listening to the DeviceTalks Weekly Podcast.
    Subscribe to the DeviceTalks Podcast Network on any major podcast player.
    57 min